Pharmacokinetics of fosamprenavir plus ritonavir in human immunodeficiency virus type 1-infected adult subjects with hepatic impairment

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 12, 2009, Pages 5185-5196

  Pérez Elías, María J ^a   Morellon, María Larrousse ^b   Ortega, Enrique ^c   Hernández Quero, José ^d   Rodríguez Torres, Maribel ^e,k   Clotet, Bonaventura ^f   Felizarta, Franco ^g   Gutiérrez, Felix ^h   Pineda, Juan A ⁱ   Nichols, Garrett ^j   Lou, Yu ^j   Wire, Mary Beth ^j  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e Fundacion de Investigacion de Diego   (Puerto Rico)

^f Hospital Germans Trias   (Spain)

^g Clinica Sierra Vista   (United States)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j GLAXOSMITHKLINE   (United States)

^k NONE   (Puerto Rico)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; BLOOD SAMPLING; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTICENTER STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTHROMBIN TIME; SIDE EFFECT; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGED; CARBAMATES; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 71249125695     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00632-09     Document Type: Article

References (9)

1. Alter, M. 2006. Epidemiology of viral hepatitis and HIV co-infection. J. Hepatol. 44(Suppl. 1):S6-S9. (Pubitemid 43053865)
2. Crum, N. F., R. Riffenburgh, S. Wegner, B. K. Agan, S. Tasker, K. M. Spooner, A. W. Armstrong, S. Fraser, and M. Wallace on behalf of the Triservice AIDS Clinical Consortium. 2006. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J. Acquir. Immune Defic. Syndr. 41:194-200.
3. Peng, J. Z., F. Pulido, S. J. Kemmis Causemaker, J. Li, A. Lorenzo, C. Cepeda, J. A. Garcia Cabanillas, B. DaSilva, S. C. Brun, and J. Arribas. 2006. Pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus coinfected subjects with hepatic impairment. J. Clin. Pharmacol. 46:265-274.
4. Pugh, R. N. H., I. M. Murray-Lyon, J. L. Dawson, M. C. Pietroni, and R. Williams. 1973. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60:646-649.
5. Rockstroh, J., D. Konopnicki, V. Soriano, O. Kirk, F. Antunes, B. Knysz, C. Tural, S. D. Wit, A. Mocroft, J. Lundgren, and the EuroSIDA study group. 2004. Hepatitis B hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS progression and response to HAART, abstr. 799. Abstr. 11th Conf. Retrovir. Opportunistic Infect., San Francisco, CA.
6. Seminari, E., A. De Bona, G. Gentilini, L. Galli, G. Schira, N. Gianotti, C. Eberti-Foppa, A. Soldarini, F. Dorigatti, A. Lazzarin, and A. Castagna. 2007. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. J. Antimicrob. Chemother. 60:831-836.
7. Soriano, V., M. Puoti, M. Sulkowski, S. Mauss, P. Cacoub, A. Cargnel, D. Dieterich, A. Hatzakis, and J. Rockstroh. 2004. Care of patients with hepatitis C and HIV co-infection. AIDS 18:1-12. (Pubitemid 38402312)
8. Veronese, L., J. Rautaureau, B. M. Sadler, C. Gillotin, J. Petite, B. Pillegand, M. Delvaux, C. Masliah, S. Fosse, Y. Lou, and D. Stein. 2000. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob. Agents Chemother. 44:821-826.
9. Wire, M. B., K. L. Baker, L. S. Jones, M. J. Shelton, Y. Lou, G. Thomas, and M. Berrey. 2006. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother. 50:1578-1580.